CUMULATIVE INDEX
Volume 27, Numbers 1-4, 1984

Abdomen
  fetal, ultrasonography of, 282-284
  injuries in pregnancy, 35-36
ABO blood group, and choriocarcinoma, 157
Abortion
  elective
    ultrasonography in, 307
    uterine rupture in, 413
  of member of multiple gestation, ultrasonography in, 293-294
  missed, ultrasonography of, 293
  in molar pregnancy, 192-194
  in renal transplant recipients, 905
  and selective feticide in multiple gestation, 356
  spontaneous
    and sexual activity in pregnancy, 710
    and ultrasonography before uterine curettage, 307-308
Abortus, hydropic, compared to hydatidiform mole, 162
Abruptio placentae, ultrasound diagnosis of, 74
Acidosis, diabetic, in pregnancy, 50-58
Actin, and myometrial contractility, 593
Actinomycin D
  in metastatic gestational trophoblastic neoplasia, 232-234
  in postmolar trophoblastic disease, 215, 217
Adenylate cyclase, complex with β-adrenergic receptors, 597-598
Adrenals
  fetal, ultrasonography of, 283-284
  and onset of labor, 563
β-Adrenergic agonists, inhibiting uterine contractility, 596-601
  efficacy of, 596
  mechanism of action, 597-600
  pharmacology of, 596-597
  side effects of, 600-601
Adrenergic blocking agents, in pregnancy with chronic hypertension, 867-868
Age
  gestational
    estimation of, 540, 617
      ultrasound in , 289, 314-325
    and preterm births, 540-545
  maternal
    and eclampsia, 814-815
    and molar pregnancy, 154-155
    and preterm birth, 546
Alcohol
  inhibiting uterine contractility, 602-603
    compared to magnesium, 601
    compared to ritodrine, 602
    efficacy of, 602
    mechanism of action, 602
    pharmacology of, 602
    side effects of, 602-603
  and sexual arousal, 772
  and sexual dysfunction, 735, 742-743
  and uterine response to oxytocin, 602
Alcoholism, in lesbians, 727-728
Allergy, and urethral syndrome, 521-522
Amenorrhea
  in anorexia nervosa, 947-948
  exercise-associated, 948-950
  hypothalamic, 945-947
Aminoglycosides, in pregnancy, 879-880
Amniocentesis
  in preterm rupture of membranes, 62, 65
  ultrasonography with
    in multiple gestation, 355-356
    risks of, 396-398
Amnion, prostaglandin synthesis in, 566-567
Amniotic band syndrome, ultrasonography in, 339
Amniotic fluid infection, and sexual activity in pregnancy, 711-712
cAMP, intracellular, and relaxation of myometrium, 599
Androgen
  serum levels in fibrocystic disease of breast, 945
  therapy with, affecting sexual function, 744
Anemia, in multiple pregnancy, 1007
Anencephaly, 78-83
Anesthesia
  in delivery of multiple fetuses, 1008
  in obstetric emergencies, 112-123
Angiotensin II, sensitivity to, in pregnancy-induced hypertension, 822-826, 838
Anorexia nervosa
  dopamine metabolism in, 947
  and low-weight amenorrhea, 947-948
Anovulation, chronic, 941-950
  in exercise-associated amenorrhea, 948-950
  in fibrocystic disease of breast, 945

in hypothalamic amenorrhea, 945-947
and induction of ovulation. *See* Ovulation, induction of
in low-weight amenorrhea and anorexia nervosa, 947-948
in polycystic ovarian syndrome, 942-945
Antibiotics in pregnancy
in preterm rupture of membranes, 65
in pyelonephritis, 24-29
in septic shock, 7
in urinary tract infections, 878-880
Antibodies, monoclonal, to chorionic gonadotropin, 244-245
Antidepressants, sexual dysfunction from, 745
Antithrombin III levels, in preeclampsia, 846-847, 869
Apgar score, assignment of, 129
Arnold-Chiari malformation, hydrocephalus in, 385
Arousal, sexual, physiologic assessment of, 768-771
Arrhythmias
from β-adrenergic agonists, 600
prenatal diagnosis and treatment of, 366-369
Asphyxia, perinatal, management of, 125-132
Aspirin, protective effects in endotoxic shock, 5
Atony of uterus, and postpartum hemorrhage, 139-141
Atropine, affecting sexual arousal, 772
Azathioprine, in pregnancy, 907-908

B thromboglobulin levels, in preeclampsia, 846
Bacteriuria
in pregnancy, 874-888
asymptomatic, 17-18, 880-883
in urethral syndrome, 520-521
Bed rest, in pregnancy with chronic hypertension, 866
Biofeedback, and sexual arousal, 774, 775
Biopsy
chorionic, in first trimester of pregnancy, 308-309
renal, in hypertension in pregnancy, 842-844, 855-857
Birth weight, low, 70-71
and delivery room management of infant, 636-645
in preterm births. *See* Preterm birth
Bladder
anatomy of, 436
detrusor instability in incontinence, 437, 454, 474-488
fetal, ultrasonography of, 284
obstruction of vesical neck, 519
retraining of, in incontinence, 485-487
ultrasonic visualization of, 277, 287
vesicoamniotic shunt placement in fetal obstructive uropathy, 384-385
vesicovaginal fistula repair, 504
Bleeding, vaginal
first-trimester, 68-70
ultrasonography in, 291-305
in hydatidiform mole, 184-185
third-trimester, 73-74
Blood flow, vaginal, measurements of, 769-770
Blood groups, and choriocarcinoma, 157
Blood transfusions
exchange, in sickle cell crisis in pregnancy, 43-44
intrauterine, in Rh sensitization, 72-73
Blood volume
and hypovolemia in preterm infants, 640-642
in pregnancy with chronic hypertension, 858
vaginal, in sleep, 777
Bones, fetal, ultrasonography of, 280-282
Bonney-Marshall test, in incontinence, 453, 461
Brain
development and growth after preterm birth, 649, 650, 652-654
fetal, ultrasonography of, 277-280
metastasis to, in gestational trophoblastic neoplasia, 229, 230-231, 234-235
Breast, fibrocystic disease of, estrogen and androgen levels in, 945
Breech presentations in labor, 95-103
congenital anomalies with, 98-99, 101
in-caul delivery in, 100
preterm, 96-100
term, 100-103
Bromocriptine, and bladder detrusor activity, 437

Calcium
channel blockers inhibiting uterine contractility, 604
efficacy of, 604
mechanism of action, 604
pharmacology of, 604
side effects of, 604
hypercalcemia in renal transplant patients, 908
and myometrial contraction, 574-575, 593-594
Calculi, renal, in pregnancy, 900
Catecholamine levels, anesthesia affecting, 113-115
Catechol-O-methyl transferase, and metabolism of β-adrenergic agonists, 597
Cerclage, cervical, preventing preterm birth, 615
Cervix uteri
cerclage preventing preterm birth, 615
competence of, and preterm birth, 618
dysplasia in lesbians, 725
lacerations in labor, 142-143
preterm dilatation of, 621
Cesarean section
in breech presentations, 99, 101
and lung mechanics in infants, 638
postmortem, 36-37
preparations for, 92-93
Chemotherapy
in metastatic gestational trophoblastic neoplasia, 232-234
in placental-site trophoblastic tumors, 256
in postmolar trophoblastic disease, 215-218
in pregnancy, affecting fetus, 907-908
Chest, fetal, ultrasonography of, 282
Chlamydial infection, urethritis in, 520
treatment of, 527

Chlorambucil, in metastatic gestational trophoblastic neoplasia, 232-234
Chlorpromazine, in septic shock, 8
Chorangiomas, placental, ultrasonography of, 336-337
Chorioadenoma destruens, 165, 248
Choriocarcinoma, 156-158, 166-170
  diagnosis in uterine curettings, 167-168
  epidemiology of, 157
  hydatidiform mole related to, 157, 166, 179
  incidence of, 156-157
  metastatic, 228-237
    to brain, 229, 230-231, 234-235
    classification of, 228-230
    to liver, 229, 231, 234-235
    to lung, 231
    staging studies in, 230-232
    treatment of, 232-236
  placental-site, 169-170, 248-256. *See also* Placental-site trophoblastic tumors
Chorionic gonadotropin
  monoclonal antibodies to, 244-245
  radioimmunoassay of, 241
  serum levels of
    in molar pregnancy, 185-186
    monitoring in trophoblastic disease, 211-213, 240-246
    in nontrophoblastic tumors, 245-246
    normal, 245
    postmolar pregnancy, 212-213
    and ultrasonographic findings, 301, 305-306
  as therapy in abnormal luteinizing hormone surge, 961
Chorionic villi sampling, in first trimester of pregnancy, 308-309
Clinical trials in preterm labor, importance of, 606-612
Clomiphene therapy, 953-963
  in follicular phase defect, 958-960
  initiation of, 957-958
  in in-vitro fertilization, 985-986
  in luteal phase defect, 960-961
  in luteinized unruptured-follicle syndrome, 062-963
  menopausal gonadotropin with, 971-972
    in in-vitro fertilization, 987-989
  monitoring with ultrasound and estrogen, 996-997
  physiologic effects of, 984
  in polycystic ovarian syndrome, 944
  schedules recommended for, 956-957
Coagulation
  disorders of
    in molar pregnancy, 186, 205
    postpartum hemorrhage in, 144-145
    in pregnancy-induced hypertension, 844-847
  disseminated intravascular
    in endotoxic shock, 4
    in pregnancy-induced hypertension, 829-830, 844-845
Cognitive development, in preterm infants, 669-670, 679
Colporrhaphy, anterior, in incontinence, 449-452
Computer use, with ultrasound in obstetrics, 416-424
Congenital anomalies, and breech presentations, 98-99, 101
Contraceptives
  intrauterine, ultrasonic location in first trimester of pregnancy, 306-307
  oral
    and choriocarcinoma, 157-158
    in polycystic ovarian syndrome, 945
    sexual dysfunction from, 745
Contractility of uterus, 573-575, 593-596. *See also* Myometrium, contractility of
Corpus luteum cyst in pregnancy, ultrasonography of, 409
Corticosteroid therapy
  in preterm rupture of membranes, 64-65
  in septic shock, 5, 7
Cortisol levels, and onset of labor, 563, 564
Counseling
  in renal disease, 894-895
  sexual
    by physicians, 782-789
    for pregnant patients and partners, 712-714
Curettage, uterine
  and choriocarcinoma diagnosis, 167-168
  in hydatidiform mole, 164, 194
  in placental-site trophoblastic tumors, 256
  in spontaneous abortion, ultrasonography with, 307-308
  vacuum suction in molar pregnancy, 192-194
Cyclophosphamide, in metastatic gestational trophoblastic neoplasia, 232-234
Cyclosporin A, in pregnancy, 908
Cyst(s)
  pelvic, in pregnancy, ultrasonography of, 409-410
  polycystic ovarian syndrome, 942-945
  polycystic renal disease in pregnancy, 899
  theca-lutein, in molar pregnancy, 186-187, 195
Cystadenoma, mucinous, in pregnancy, 410
Cystitis
  acute, in pregnancy, 883-884
  compared to detrusor instability, 482-483
Cystometry
  in urethral syndrome, 523
  in urinary incontinence, 440-441, 454, 479-480
Cystoscopy, in urethral syndrome, 523
Cystourethrocele, incontinence in, 453, 461
Cystourethrogram, in incontinence, 442, 461-463

Dandy-Walker syndrome, hydrocephalus in, 386
Delivery
  of multiple fetuses, 1008-1010
  premature. *See* Preterm birth
Depression, sexual dysfunction in, 742
Dermoid cysts in pregnancy, ultrasonography of, 410-411
Diabetes mellitus
  eclampsia in , 815

and ketoacidosis in pregnancy, 50-58
affecting fetus, 54
clinical features of, 55-56
diagnosis of, 56
management of, 56-58
pathophysiology of, 51-52
predisposing factors in, 52-55
prevention of, 58
sexual dysfunction in, 743
Diazepam
in bladder detrusor instability, 487
in urethral spasm, 526-527
Dicyclomine, in bladder detrusor instability, 487
Digitalis, in septic shock, 8
Diverticulum of urethra, 490-498
Dopamine
metabolism in anorexia nervosa, 947
as therapy in endotoxic shock, 5, 8
Drug use, and sexual dysfunction, 735, 742-743
Dyspareunia, 750-759
assessment of factors in, 750-752
diffuse or unilateral deep discomfort in, 758-759
factors in, 734
in menopause, 720
organic factors in, 756-757, 758
physical examination in, 753-754
theoretic causes of, 752-753
in urethral syndrome, 757
at vaginal apex, 757-758
in vaginismus, 736, 754-756
Dystocia
breech, 95-103
shoulder, 106-111

Echocardiography, fetal, 282, 359-376
in arrhythmias, 366-369
choice of equipment in, 362
in cogenital heart defects, 373-374
image display in, 361-362
M-mode, 359-360
quantitation of, 366
real-time directed, 360-361
in pericardial effusion, 371-373
real-time, 360
structure and function evaluation in, 363-365
in ventricular dysfunction, 369-371
Eclampsia. *See also* Hypertension in pregnancy
epidemiology of, 811-820
historical aspects of, 801-809
mortality from, related to management, 804-807
prophylaxis of, 808-809
Ectopic pregnancy
diagnosis of, 69-70
intrauterine pregnancy with, 1007-1008
screening for, 299
ultrasonography of, 297-305
Edema
in eclampsia, 802
pulmonary, from β-adrenergic agonists, 600
Ejaculatory orgasms in females, 701-705
Electromyography, in urinary incontinence, 442
Embolization to lung, in molar pregnancy, 186, 201
Embryo transfer programs, 983-990
Emergencies, obstetric, 3-150
acute fetal distress in labor, 84-93
anesthesia for, 111-123
breech presentations, 96-103
diabetic ketoacidosis, 50-58
in-utero transport in, 11-16
inversion of uterus, 134-137, 142
neural tube defects, 78-83
postpartum hemorrhage, 139-146
preterm rupture of membranes, 60-66
pyelonephritis, 17-29
review questions on, 149-150
septic shock, 3-9
shoulder dystocia, 106-111
sickle cell crisis, 39-48
trauma, 32-37
ultrasound in, 68-76
Endocrine factors
in menstrual cycle, 919-923
in myometrial contractility, 581-588
in preterm birth, 563-568
in sexual arousal, 772
in sexual dysfunction, 746
Endometriosis, in lesbians, 726
Endometritis, syncytial, 169, 248
differential diagnosis of, 256
Endotoxic shock, pathophysiology of, 3-6
Epinephrine, as adrenergic agonist, 596-597
Erotic material, affecting sexual arousal, 771-772
Erythrocytapheresis, automated, in sickle cell crisis in pregnancy, 43-44
Estrogen
hypoestrogenic urethritis, 517-518
serum levels of
in fibrocystic disease of breast, 945
and myometrial contractility, 582
and onset of labor, 563-564
and pituitary gonadotropin release, 922-923
and ultrasound monitoring of ovulation induction, 993-1001
therapy with
as pretreatment in menopausal gonadotropin therapy, 972-973
and sexual activity in menopause, 720-722, 776
Ethanol. *See* Alcohol
Ethrane, in obstetric anesthesia, 116
Etoposide, in metastatic gestational trophoblastic neoplasia, 236
Exercise
amenorrhea from, 948-950
and preterm birth, 615, 619-620

Families of preterm infants
characteristics of, 679-682

stresses in, 676-677, 681-682
Fantasy, and sexual arousal, 772-773, 775
Fecal impaction in pregnancy, ultrasonography of, 413
Fertility, and chronic anovulation, 941-950
Fertilization programs, in-vitro, 983-990
Fetus
abdominal circumference in, 320-322
in growth retardation, 345
in macrosomia, 349
in multiple gestation, 354
acute distress in labor, 84-93
anesthesia affecting, 117-119
biparietal diameter in, 315-319
in growth retardation, 344
and lecithin/sphingomyelin ratio, 393
in macrosomia, 349
in multiple gestation, 354
crown-rump measurements in, 290-291, 315
in growth retardation, 344
echocardiography of, 282, 359-376
femur length in, 322-323
in growth retardation, 345
head circumference in, 319-320
in growth retardation, 344-345
in multiple gestation, 354
heart rate monitoring, 86-88
in preterm labor, 636
ketoacidosis affecting, 54
lung maturity diagnosis, 391-399
and arguments against ultrasonography, 395-396
and arguments for ultrasonography, 398-399
invasive approaches in, 391-392
lecithin/sphingomyelin ratio in, 392
noninvasive approaches in, 392-395
and risk of amniocentesis, 396-398
maternal hypertension affecting, 860-861
maternal renal transplant affecting, 906-907, 909-910
maternal urinary tract infections affecting, 877-878
in molar pregnancies, 183-184, 195-197
multiple gestation affecting, 354, 1004-1005
neural tube defects in, 78-83
prostaglandin formation in, and onset of labor, 564-568
scalp pH assessment, 91
status evaluation by ultrasound, 75-76
transition to neonatal life, 637
treatment in utero, 378-389
in arrhythmias, 369
and classification of anomalies, 379-380
in hydrocephalus, 385-388
international registry for, 388
in obstructive uropathies, 380-385
ventriculoamniotic shunts in, 81, 387-388
vesicoamniotic shunts in, 384-385
ultrasonographic anatomy of, 277-285. *See also* Ultrasound in obstetrics
weight of
estimates of, 70-72
in growth retardation, 346
in macrosomia, 349
Fibrocystic disease of breast, estrogen and adrogen levels in, 945
Fistulas, genitourinary, 499-513
etiology of, 499-501
postoperative care in, 513
prevention of, 501
recognition of, 501
route of repair in, 503-504
surgery in, 504-513
in irradiation-induced fistulas, 511-513
timing of, 502-503
in urethrovaginal fistula, 505-511
in vesicovaginal fistula, 504
Flavoxate, in bladder detrusor instability, 487
Fluid replacement
in diabetic ketoacidosis in pregnancy, 57
in sickle cell crisis in pregnancy, 44-45
Fluorescent antibody-coated bacteria test, in urinary tract infections, 877
Follicle-stimulating hormone
and folliculogenesis, 927-938
secretion in anorexia nervosa, 948
secretion in menstrual cycle, 919-920
steroids affecting release of, 922-923
Folliculogenesis, ovarian, gonadotropins affecting, 927-938
Foreplay, and sexual response, 788

G spot, in vagina, 701-705
Gallbladder, fetal, ultrasonography of, 283
Genetic factors
in eclampsia, 812-813
in molar pregnancy, 156, 174-177, 181
Genitalia, fetal, ultrasonography of, 284
Genitourinary conditions. *See* Urology
Gestational age
estimation of, 70
ultrasound in, 289, 314-325
and preterm births, 540-545
Glomerulonephritis in pregnancy, 896
Glucose levels
in endotoxic shock, 4
insulin affecting, 50-51
Gonadotropin
chorionic. *See* Chorionic gonadotropin
menopausal. *See* Menopausal gonadotropin
pituitary, 91-923
releasing hormone, in ovulation induction, 975-981
administration of, 976-977
for multiple ovulation, 980
protocol for, 977-979
Gräfenberg spot, 701-705
Growth
after preterm birth, 647-661
retardation of, intrauterine, 71-72
ultrasonography of, 342-347
Gunshot wounds, abdominal, in pregnancy, 35

Habitus, and eclampsia, 815-816
Halothane, in obstetric anesthesia, 116
Head circumference, and growth after preterm birth, 650, 652-654
Heart
  in endotoxic shock, 3-4
  fetal, ultrasonography of, 282, 359-376
  in molar pregnancy, 203
Heart rate, fetal, monitoring of, 86-88
  in preterm labor, 636
Heat loss, in neonates, 643
Hematoma
  of abdominal wall, in pregnancy, ultrasonography of, 413
  pelvic, postpartum, 142-143
Hemorrhage, postpartum, 139-146
Herpes infection, in lesbians, 725
History-taking, in sexual dysfunction, 733-735, 785-786
HLA antigens, and choriocarcinoma, 157
Homosexual women. *See* Lesbians
Hormones. *See* Endocrine factors
Hyaline membrane disease, and diagnosis of fetal lung maturity, 391-399
Hydatidiform mole, 153-156. *See also* Mole, hydatidiform
Hydralazine, in pregnancy with chronic hypertension, 868
  with preeclampsia, 871
Hydramnios
  polyhydramnios in multiple pregnancy, 1007
  and preeclampsia, 815
Hydrocephalus
  neural tube defects with, 78-83
  in premature breech infants, 98-99
  treatment in utero, 385-388
    ventriculoamniotic shunt in, 81, 387-388
Hydropic abortus, compared to hydatidiform mole, 162
Hydrops, fetal, and preeclampsia, 814
Hyperemesis gravidarum, in molar pregnancy, 185
Hypertension in pregnancy
  adrenergic nerves in, 859
  angiotensin sensitivity in, 822-826, 838
  antihypertensive drugs in, 866-868
  bed rest in, 866
  blood pressure measurements in, 839-840, 855
  blood volume in, 858
  chronic hypertension antedating pregnancy, 854-872
  coagulation tests in, 844-847
  diagnosis of, 836-849, 861-864
  eclampsia in, 803-804
  fetal effects of, 860-861
  hepatic function tests in, 848-849
  immunologic factors in, 831-832
  induced by pregnancy
    clinical features and diagnosis of, 836-849
    pathophysiology of, 821-832, 837
  management of, 864-868
  maternal effects of, 858-860
  peripheral vascular resistance in, 858
  preeclampsia in, 870-872
  prostaglandin action in, 827-831
  renal biopsy in, 842-844, 855-857
  in renal disease, 892, 895
  renal function tests in, 841-844
  in renal transplant recipients, 905-906
  review questions on, 915-916
  rollover test in, 838-839, 870
  uric acid levels in, 840, 844, 869
  uteroplacental bed in, 859-860
  vasoconstrictor tone in, 822-827
Hypotension, from β-adrenergic agonists, 600
Hypothalamic amenorrhea, 945-947
Hysterectomy
  in molar pregnancy, 195
  in placental-site trophoblastic tumors, 256
  in septic shock, 8
  in urinary incontinence, 452, 456, 457, 472
Hysterotomy, in molar pregnancy, 195

Imipramine, in bladder detrusor instability, 487
Immune mechanisms, in pregnancy-induced hypertension, 831-832
Immunosuppressive drugs, in pregnancy, 907-908
Incest, sexual dysfunction after, 741
Incontinence, urinary, 434-443
  anatomic factors in, 436, 440, 446-449
  anterior colporrhaphy in, 449-452
  bladder retraining in, 485-487
  Bonney-Marshall test in, 453, 461
  comparison of vaginal and suprapubic surgery in, 449-452, 457
  cystometry in, 440-441, 454, 479-480
  in cystourethrocele, 453, 461
  cystourethrogram in, 442, 461-463
  definitions of, 434, 447
  in detrusor instability, 437, 454, 474-488
    clinical features of, 478-479
    diagnosis of, 479-481
    differential diagnosis of, 481-485
    medical management of, 437, 485-487
    surgery in, 487-488
  diagnostic procedures in, 439-440, 453-456, 479-481
  electromyography in, 442
  in genitourinary fistulas, 499-513
  hysterectomy in, 452, 456, 457, 472
  medical management of, 437, 485-487
  myths concerning, 449-453
  operative technique in, 464-471
  and pathophysiology of micturition, 437-438
  postoperative management in, 471
  radiologic studies in, 442-443
  recurrent, 459
  selection of operative procedures in, 456-457
  in sexual activity, 705, 719
  surgery in, 449-452, 464-471, 487-488
  treatment of, 445-457

urethral pressure in, 441
urethroscopy in, 422, 464
uroflowmetry in, 441
Indomethacin
in bladder detrusor instability, 487
inhibiting uterine contractility, 603-604
Infants, low birth weight. *See* Preterm birth
Infection
amniotic fluid, and sexual activity in pregnancy, 711-712
in molar pregnancy, 186
and preterm birth, 61, 618
pyelonephritis in pregnancy, 17-29, 884-886, 898
in renal transplant recipients, 906
and septic shock in obstetrics, 3-9
in sickle cell crisis in pregnancy, 42
and urethral syndrome, 520-521
treatment of, 527
urinary tract, in pregnancy, 874-888
vaginal, in lesbians, 724-725
Infertility
and chronic anovulation, 941-950
medical aspects of, 760-762
psychological reactions to, 762
sexual reactions to, 744, 762-766
Insulin
metabolic effects of, 50-51
therapy in diabetic ketoacidosis in pregnancy, 56-57
Intellectual development, in preterm infants, 669, 679
Iron levels in serum, in preeclampsia, 847, 869
Isoxoprine, inhibiting uterine contractility, 596-601

Kegel exercises, 705, 776, 788
Ketamine, in obstetric anesthesia, 116
Ketoacidosis, diabetic, in pregnancy, 50-58
Kidney
alterations in pregnancy, 891-892
chronic disease in pregnancy, 891-900
counseling and management in, 894-896
diabetic nephropathy, 899
glomerulonephritis, 896
lupus erythematosus, 896-898
nephrotic syndrome, 899
and outcome of pregnancy, 893, 895
periarteritis nodosa, 898
perinatal outcome in, 894
polycystic disease, 899
pyelonephritis, 17-29, 884-886, 898
scleroderma, 898
solitary kidney, 899
urinary diversion in, 898
urolithiasis, 900
in endotoxic shock, 4
fetal, ultrasonography of, 283
function tests in pregnancy-induced hypertension, 841-844
pelvic, in pregnancy, ultrasonography of, 413
transplant recipients, pregnancy in, 902-912
abortion in, 905
hypertension in, 905-906
infections in, 906
management of, 908-910
perinatal outcome in, 906-908
postpartum care in, 910-911
and rejection of allograft, 904-905

Labetalol, in pregnancy with chronic hypertension, 867, 868
Labor
acute fetal distress in, 84-93
breech presentations in, 95-103
delayed by tocolytic agents, 592-605. *See also* Tocolytic agents
in multiple gestation, 74-75, 1009-1010
myometrial function in, 572-590
onset of, mechanisms in, 563-568
and myometrial contractility, 572-590, 593-596
and postpartum hemorrhage, 139-146
premature. *See* Preterm birth
prostaglandin-induced, in fetal anencephaly, 80-81
shoulder dystocia in, 106-111
sickle cell crisis management in, 46
uterine inversion in, 134-137, 142
Lacerations, cervical and vaginal, 142-143
Lactation, and sexual activity, 714
Lesbians
acquired immunodeficiency syndrome in, 725
alcoholism in, 727-728
cervical dysplasia in, 725
endometriosis in, 726
interaction with physicians, 728-730
menstrual cycle disorders in, 725-726
pregnancy-related concerns in, 726
sexual dysfunction in, 726-727
sexually transmitted diseases in, 725
vaginal infections in, 724-725

Liver
in endotoxic shock, 4
fetal, ultrasonography of, 282
function tests in pregnancy-induced hypertension, 848-849
metastasis to, in gestational trophoblastic neoplasia, 229, 231, 234-235
Lungs
embolization to, in molar pregnancy, 186, 201
in endotoxic shock, 4
fetal
maturity evaluation of, 391-399
ultrasonography of, 282
metastasis to, in gestational trophoblastic neoplasia, 231
surfactant administration in respiratory distress syndrome, 638
Lupus anticoagulant activity, in pregnancy-induced hypertension, 831
Lupus erythematosus in pregnancy, 896-898

Luteinizing hormone
abnormal surge of, 961
and folliculogenesis, 927-938
releasing hormone, 920-921
secretion in anorexia nervosa, 948
secretion in menstrual cycle, 919-920
steroids affecting release of, 922-923
Lyon's ring, urethral, 518-519

Macrosomia of fetus, ultrasonography in, 347-348
Magnesium
inhibiting uterine contractility, 90, 601-602
compared to alcohol, 601
efficacy of, 601
mechanism of action, 601
pharmacology of, 601
side effects of, 602
in preeclampsia with chronic hypertension, 870-871
Masturbation, as treatment of sexual problems, 787-788
Membrane rupture, preterm, 60-66
Menopausal gonadotropin
in ovulation induction, 963, 966-973
clomiphene with, 971-972
in in-vitro fertilization, 987-989
estrogen pretreatment in, 972-973
in in-vitro fertilization, 986-987
monitoring with ultrasound and estrogen, 997-1001
physiologic effects of, 984-985
Menopause
and hypoestrogenic urethritis, 517
sexual function in, 717-723, 745
vaginal engorgement in, 775-776
Menstrual cycle
disorders in lesbians, 725-726
endocrinology of, 919-923
follicular phase in, 931-937
ideal normal cycle in, 955-956
luteal phase in, 929-931
and sexuality, 745, 773
Mercaptopurine, in pregnancy, 908
Metaraminol, in septic shock, 8
Methantheline, in bladder detrusor instability, 487
Methotrexate
in metastatic gestational trophoblastic neoplasia, 232-234
in postmolar trophoblastic disease, 215, 217
Methyldopa, in pregnancy with chronic hypertension, 867, 868
Microangiopathy, in pregnancy-induced hypertension, 830-831, 845
Micturition
and incontinence, *See* Incontinence, urinary
neurologic control of, 437-438, 446, 475
pathophysiology of, 437-438
Mole, hydatidiform, 153-156
blood volume expansion in, 203-205
cardiogenic dysfunction in, 203
and choriocarcinoma development, 157, 166, 179
clinical features of, 184-186
coagulation abnormalities in, 186, 205
complete, 172-173, 178, 181
complications of, 186-187, 199-207
diagnosis of, 161-162, 187-189
eclampsia in, 814
epidemiology of, 154-156
familial, 156
fetus and mole in, 183-184, 195-197
follow-up of, 211-213
genetic factors in, 156, 174-177, 181
grading of, 164
histology of, 163
hysterectomy in, 195
hysterotomy in, 195
incidence of, 153-154
invasive, 165-166
and monitoring system for patients, 211-213, 240-246
oxytocic agents in, 194-195
partial, 163-164, 173-174, 178-179, 181
and postmolar trophoblastic disease, 211-219
chorionic gonadotropin levels in, 212-213
diagnosis of, 214-215
treatment of, 215-218
recurrence of, 155-156, 223
reproductive performance after, 221-226
respiratory complications in, 186, 201-203
and Rh immune globulin administration, 197
sharp curettage in, 164, 194
and termination of pregnancy, 192-198
thyrotoxicosis in, 186, 199-201
in twin pregnancies, 156, 183-184
ultrasonography in, 295-297
vacuum suction curettage in, 192-194
Monitoring
of fetal heart rate, 86-88
in trophoblastic disease, 211-213, 240-246
Monoamine oxidase, and metabolism of β-adrenergic agonists, 597
Monoclonal antibodies, to chorionic gonadotropin, 244-245
Mortality
in eclampsia, related to management, 804-807
in preterm births, 543, 545-546
Multiple gestation
abortion of member of, 293-294
after ovulation induction, 980, 1003-1011
anemia in, 1007
diagnosis of, 1004
eclampsia in, 813

ectopic and intrauterine pregnancy in, 1007-1008
fetal development in, 1004-1005
and hydatidiform moles, 156, 183-184
intrapartum management of, 74-75
labor and delivery in, 1009-1010
anesthesia for, 1008
maternal physiologic changes in, 1004
outcomes of, 1010-1011
polyhydramnios in, 1007
preeclampsia in, 1007
premature delivery in, 543-544, 1005-1007
selective feticide in, 356
ultrasonography in, 352-357
Myocardial depressant factor, in endotoxic shock, 3
Myomas, uterine, in pregnancy, ultrasonography of, 404-407
Myometrium
contractility of, 573-575, 593-596
hormonal control of, 581-588
inhibition with tocolytic agents, 592-605. *See also* Tocolytic agents
myogenic control of, 576-579
neurogenic control of, 579-581
in orgasm, 700-701
oxytocin affecting. *See* Oxytocin infusions pacemaker activity in, 576
and propagation of electrical activity, 576-579
electrical and mechanical activity of, 573-575
function in labor, 572-590
structure of, 573
Myosin, and myometrial contractility, 593

Neonates
low birth weight. *See* Preterm birth
resuscitation of, 125-132
Nephrotic syndrome, in pregnancy, 899
Nervous system
central, metastasis to, in gestational trophoblastic neoplasia, 229, 230-231, 234-235
development in preterm infants, 650, 656-657, 664-671
sympathetic, anesthesia affecting, 113-115
Neural tube defects, 78-83
Nifedipine
in bladder detrusor instability, 487
inhibiting uterine contractility, 604
Norepinephrine, as adrenergic agonist, 596-597
Nutrition, and preterm birth, 553-559

Obstetric care. *See* Pregnancy
Oligohydramnios, and intrauterine growth retardation, 346-347
Opiates, in control of menstrual cycle, 946
Orgasm, female, 700-701
dysfunction in, 736-737, 739-740
ejaculatory, 701-705
physiologic assessment of, 771, 773-774
Ovaries
folliculogenesis affected by gonadotropins, 927-938
polycystic ovarian syndrome, 942-945
diagnosis of, 944
pathophysiology of, 942-944
treatment of, 944-945
tumors in pregnancy, ultrasonography of, 407-409
ultrasonic visualization of, 288
Ovulation
chronic anovulation, 941-950
and endocrinology of menstrual cycle, 919-923
induction of
clomiphene in, 944, 953-964
and complications of multiple gestation, 1003-1011
gonadotropin-releasing hormone in, 975-981
for in-vitro fertilization programs, 983-990
clomiphene in, 985-986
experience during one year, 989
gonadotropin-releasing hormone in, 980
menopausal gonadotropin in, 986-987
and multiple pregnancy rate, 989-990
menopausal gonadotropin in, 963, 966-973
monitoring with ultrasound and estrogen, 993-1001
in clomiphene-induced cycles, 996-997
in menopausal gonadotropin-induced cycles, 997-1001
review questions on, 1015-1016
Ovum, blighted, ultrasonography of, 292-293
Oxybutinin, in bladder detrusor instability, 487
Oxytocin infusions
in molar pregnancy, 194
and myometrial contractility, 89, 586-588
alcohol affecting, 602
in uterine atony, 140-141

Pancreas, fetal, ultrasonography of, 283
Parity
and eclampsia, 811-812
and preterm birth, 547-549
Parturition. *See* Labor
Pelvic congestion syndrome, and dyspareunia, 758
Pelvis, maternal
masses in, ultrasonography of, 402-414
ultrasonographic anatomy of, 277, 287
Penicillin, in septic shock, 7
Pergonal. *See* Menopausal gonadotropin
Periarteritis nodosa, in pregnancy, 898
Phenoxybenzamine, in urethral spasm, 527
Phosphatidylinositol hydrolysis, and activation of muscle contraction, 594
Physical exertion, and preterm birth, 615, 619-620

Physicians
interaction with lesbian patients, 728-730
as sexual counsellors, 782-789
Pituitary gland function, and onset of labor, 563
Pituitary gonadotropins, 919-923
and folliculogenesis, 927-938
Placenta
abruption of, ultrasound diagnosis of, 74
accreta, 143-144
maturational changes in, 329-334
and growth retardation, 347
and lung maturity, 393-395
percreta, 143
praevia
and preterm birth, 618
ultrasound diagnosis of, 73-74
retention of, 143-144
role in onset of labor, 563
Placental-site trophoblastic tumors, 169-170, 248-256
clinical features of, 249
differential diagnosis of, 255-256
follow-up studies of, 252-255
pathology of, 249-252
treatment of, 256
Placentography, ultrasonic, 327-340. *See also* Ultrasound in obstetrics, placental imaging in
Polyhydramnios
in multiple pregnancy, 1007
and preeclampsia, 815
Prednisone, in pregnancy, 907
Preeclampsia
and chronic hypertension, treatment of, 870-872
in chronic renal disease, 892, 895
diagnosis of, 809, 810-811
and hydatidiform mole, 185, 204
in multiple pregnancy, 1007
Pregnancy
after trophoblastic disease, 221-226
and choriocarcinoma, 166
diabetic ketoacidosis in, 50-58
eclampsia in, *See* Eclampsia
ectopic. *See* Ectopic pregnancy
emergencies in, 3-150. *See also* Emergencies, obstetric
hypertension in. *See* Hypertension in pregnancy
in lesbians, 726
molar, 153-156. *See also* Mole, hydatidiform
multiple. *See* Multiple gestation
and neural tube defect diagnosis, 78-83
pelvic masses in, ultrasonography of, 402-414
preterm rupture of membranes in, 60-66. *See also* Preterm birth
pyelonephritis in, 17-29, 898
renal alterations in, 891-892
renal disease in, chronic, 891-900
in renal transplant recipients, 902-912
Rh sensitization in, 72-73
septic shock in, 3-9
in pyelonephritis, 20-24
sexuality in, 706-715, 743-744
sickle cell crisis in, 39-48
trauma in, 32-37
and treatment of fetus in utero, 81, 387-388
ultrasound in, 267-427. *See also* Ultrasound in obstetrics
urinary tract infections in, 874-888
vaginal bleeding in
first-trimester, 68-70
third-trimester, 73-74
Premature rupture of membranes, 60-66. *See also* Preterm birth
diagnosis of, 61-62
etiology of, 61
management of, 62-65
Premenstrual syndrome, sexual dysfunction in, 745
Prenatal diagnosis of disorders
chorionic villi sampling in, 308-309
ultrasonography in. *See* Ultrasound in obstetrics
Preterm birth, 537-694
breech presentation in, 96-100
cervical cerclage affecting, 615
cervical competence affecting, 618
and characteristics of families of infants, 679-682
and characteristics of low birth weight infants, 677-679
and cognitive development, 669-670, 679
definition of, 616-617
and delivery room management of infant, 636-645
alkali infusions in, 640
endotracheal intubation in, 639
in hypovolemia, 640-642
and limits of resuscitation, 645
lung surfactant administration in, 638
in respiratory distress syndrome, 637-640
and risk of iatrogenic problems, 644-645
thermoregulation in, 642-644
endocrinology of, 562-568
growth after, 647-661
and brain development, 649, 650
caretaking affecting, 655
catch-up growth in, 649, 650, 652-653, 659
and chronic disease incidence, 656
correlated of, 654
and developmental outcome, 657
and effects of subnormal weight, 657-658
and neonatal risk scores, 654-655
and neurologic abnormalities, 650, 656-657
patterns of growth in, 652-654
historical studies of, 615-616
and identification of at-risk infants, 672-675

in infections, 618
and interventions affecting development, 684-689
home-based, 687
hospital-based, 684-687
hospital and home-based, 687-688
infant-focused, 684-685, 687
parent-focused, 685-686, 687
parent-infant-focused, 686, 687-688
intrapartum management of, 636-637
and maternal age, 546
and mechanisms in onset of labor, 563-568
medical conditions affecting, 549
in multiple gestation, 543-544, 1005-1007
myometrial function in, 572-590
and neurologic development, 650, 656-657, 664-671
perinatal variables in, 668-671
predictors of outcome in, 665-667
and nutrition during pregnancy, 553-559
dietary supplementation in, 557-559
undernutrition in, 555-556
parity affecting, 546-549
and perinatal mortality, 543, 545-546
physical exertion affecting, 615, 619-620
placenta praevia in, 618
predictors of, 620-621
and prenatal work leave, 615-616, 620, 627
prevention program for, 614-632
educational efforts in, 625, 629, 631
organization of, 624-627
results of, 627-631
tocolytic agents in, 592-605. *See also* Tocolytic agents
and psychomotor development, 678
in pyelonephritis of pregnancy, 23
racial factors in, 542-543
in renal transplant patients, 907
and resuscitation in infants, 132
review questions on, 694
risk factors in, 539-550, 617-618, 679-680
scoring system for, 622-624
and sexual activity in pregnancy, 711
socioeconomic factors in, 549-550, 615, 630
affecting nutrition, 556
and stresses affecting families, 676-677, 681-682
in successive pregnancies, 545, 617
and temperament of infants, 678-679
Progesterone
serum levels of
and myometrial contractility, 581-582
and onset of labor, 564
and pituitary gonadotropin release, 923
suppository therapy in luteal-phase defect, 960-961
Propantheline, in bladder detrusor instability, 487
Propranolol, in pregnancy with chronic hypertension, 867-868
Prostaglandins
activity in pregnancy-induced hypertension, 827-831
in endotoxic shock, 5
inhibitors of, inhibiting uterine contractility, 603-604
efficacy of, 603
mechanism of action, 603
pharmacology of, 603
side effects of, 604
in labor induction with fetal anencephaly, 80-81
in molar pregnancy, 194
and myometrial contractility, 583-586, 594
and onset of labor, 564-568
in uterine atony, 141
Protein kinase A, and relaxation of myometrium, 599
Proteinuria, in eclampsia, 802-803
Pseudotumor, trophoblastic, 169, 248-256. *See also* Placental-site trophoblastic tumors
Psychologic aspects
of dyspareunia, 751, 752-753
of infertility, 762
of inhibited sexual desire, 741-742
of urethral syndrome, 521
of vaginismus, 755-756
Pubococcygeal muscle strength, and sexual response, 705, 776, 788
Pyelography, intravenous, in incontinence, 442
Pyelonephritis in pregnancy, 17-29, 884-886, 898
clinical features of, 19-20
complications of, 20-24
premature delivery in, 23
prevention of, 24
treatment of, 24-29

Race
and eclampsia, 816
and preterm birth, 542-543
Radiation, genitourinary fistulas from, repair of, 511-513
Radioimmunoassay of chorionic gonadotropin, 241
Radiology
in urethral syndrome, 523-524
in urinary incontinence, 442-443
Rape, sexual dysfunction after, 741-742
Relaxation of smooth muscle, mechanisms in, 599-600
Relaxin, and myometrial contractility, 588
Religiosity, and sexual dysfunction, 741
Respiratory complications in molar pregnancy, 201-203
Respiratory distress syndrome in preterm infants, management of, 637-640
Resuscitation of infants
intrauterine, 89-92
neonatal, 125-132
in preterm birth, 636-645

Rh sensitization
  and immune globulin in molar pregnancy, 197
  intrauterine transfusions in, 72-73
Ritodrine, inhibiting uterine contractility, 596-601
  compared to ethanol, 602
Rollover test, in hypertension in pregnancy, 838-839, 870
Rupture
  of membranes, preterm, 60-66
  of uterus, postpartum, 141

Scleroderma, in pregnancy, 898
Sensate focus exercises, in sexual dysfunction, 746, 748, 788
Septic shock in obstetrics, 3-9
  in pyelonephritis, 20-24
Sexual activity
  dysfunction in. *See* Sexual dysfunction
  and gynecologic care for lesbians, 724-730
  lactation affecting, 714
  in menopause, 717-723, 745
    estrogen therapy affecting, 720-722
  physiologic responses in. *See* Sexual response in females
  postgestational, 714-715
  in pregnancy, 706-715, 743-744
    and adverse pregnancy outcome, 709-712
    counseling on, 712-714
Sexual dysfunction
  alcohol and drug history in, 735, 742-743
  in chronic illness, 743
  clinical markers of, 774-775
  in depression, 742
  and dyspareunia, 750-759
  in endocrinopathies, 746
  history-taking in, 733-735, 785-786
  in infertility, 744, 762-766
  inhibited sexual desire in, 735-736, 738-739
    treatment of, 746-747
  in lesbians, 726-727
  in menstrual cycle phases, 745
  and negative past experiences, 741-742
  onset and antecedents of, 734-735
  orgasmic dysfunction in, 736-737, 739-740
    treatment of, 747-748
  pharmacologic agents causing, 744-745
  relationship issues in, 735, 740-741, 787
  screening for, 732-737
  sensate focus exercises in, 746, 748, 788
  in vaginismus, 736
Sexual response in females, 697-705
  arousal in, 699
    biofeedback affecting, 774-775
    drugs and hormones affecting, 772
    erotic material affecting, 771-772
    fantasy related to, 772-773, 775
    and menstrual cycle, 773
    physiologic assessment of, 768-771
  excitement in, 699
  G spot in, 701-705
  orgasm in, 700-701
    physiologic assessment of, 771, 773-774
  physiologic assessment of, 767-778
    in arousal phase, 768-771
    in orgasm phase, 771, 773-774
    in sleep, 777
    plateau stage in, 700
    and pubococcygeal muscle strength, 705, 776, 788
    resolution phase in, 701
    vaginal engorgement in
      physiologic measures of, 769-770
      postmenopausal, 775-776
      in sleep, 777
    vaginal lubrication in, 699-700, 770
Sexual therapy
  counseling techniques in, 783-785
    for pregnant patients and partners, 712-714
  directed masturbation in, 787-788
  foreplay in, 788
  history-taking in, 733-735, 785-786
  sensate focus exercises in, 746, 748, 788
Shoulder dystocia, 106-111
Sickle cell disease, and crises in pregnancy, 39-48
  antepartum care in, 43-45
  diagnostic aids in, 42
  intrapartum care in, 46
  pathogenesis of, 39-41
  postpartum care in, 46
  types of, 41
Skeletal system, fetal, ultrasonography of, 280-282
Sleep, vaginal blood volume in, 777
Smoking, maternal
  and effects of nutrition, 559
  and pregnancy outcome, 554
Socioeconomic factors
  in eclampsia, 817
  in preterm birth, 549-550, 615, 630
    and outcomes for infants, 650, 682
Spina bifida, 78-83
Spine, fetal, ultrasonography of, 280-281
Spleen, fetal, ultrasonography of, 283
Stab wounds, abdominal, in pregnancy, 35-36
Stein-Leventhal syndrome, 942-945
Stomach, fetal, ultrasonography of, 283
Stress in families, and infant development, 676-677, 681-682
Sulfonamides, in pregnancy, 880
Surgery. *See also* Cesarean section; Hysterectomy

in diverticulum of urethra, 493-497
in genitourinary fistulas, 504-513
in septic shock, 8-9
in urinary incontinence, 449-452, 464-471, 487-488
Sylvian aqueduct stenosis, hydrocephalus in, 385-386
Sympathetic nervous system, anesthesia affecting, 113-115
Syncytial endometritis, 169, 248
differential diagnosis of, 256

Temperature regulation, neonatal, 642-644
Terbutaline, inhibiting uterine contractility, 596-601
Tetracycline, in pregnancy, 878-879
Theca-lutein cysts
in molar pregnancy, 186-187, 195
in pregnancy, ultrasonography of, 410
Thermography studies of sexual arousal, 770
Thrombocytopenia, microangiopathic, in pregnancy-induced hypertension, 829-831, 845-846
Thrombophlebitis, septic pelvic, 8-9
Thyrotoxicosis, in molar pregnancy, 186, 199-201
Tocolytic agents, 592-605
β-adrenergic agonists, 596-601
alcohol, 602-603
calcium channel blockers, 604
clinical trails of, need for, 606-612
magnesium, 601-602
prostaglandin inhibitors, 603-604
Toxemia, preeclamptic, and hydatidiform mole, 185
Transfusions
exchange, in sickle cell crisis in pregnancy, 43-44
intrauterine, in Rh sensitization, 72-73
Transport, maternal, in obstetric emergencies, 11-16
Trauma in pregnancy, 32-37
blunt abdominal, 36
penetrating abdominal, 35-36
and postmortem cesarean section, 36-37
Trimethoprim-sulfamethoxazole, in pregnancy, 879
Trophoblastic disease, 151-260
complications of, 186-187, 199-207
diagnosis and clinical features of molar pregnancy, 181-189
differential diagnosis of, 162
epidemiology of, 153-158
monitoring of, 211-213, 240-246
partial and complete molar gestation, 172-179
pathologic considerations in, 160-170
placental-site tumor, 169-170, 248-256
poor-prognosis metastatic, 228-237
postmolar, 211-218
pregnancy termination in, 192-197
presentation and diagnosis of, 181-189
reproductive performance after, 221-226
review questions on, 259-260
ultrasonography of, 295-297
Tumors
trophoblastic, 151-260. *See also* Trophoblastic disease and ultrasonography of pelvic masses in pregnancy, 402-414
Twin pregnancies. *See* Multiple gestation

Ultrasound in obstetrics, 267-427
amniocentesis with
in multiple gestation, 355-356
risks of, 396-398
biologic effects of
epidemiology of, 273
experimental, 269-272
mechanisms in, 272-273
in breech presentations, 95-96
computer use with, 416-424
advantages of, 422-423
limitations of, 423-424
echocardiography of fetus in, 282, 359-376. *See also* Echocardiography, fetal
in emergencies, 68-76
fetal anatomy in, 277-285
abdomen, 282-284
chest, 282
genitalia, 284
intracranial, 277-280
skeletal system, 280-282
in fetal status evaluation, 75-76
in fetal weight estimation, 70-72
in first trimester of pregnancy, 286-309
in abortion of member of multiple gestation, 293
biometry in, 289-291
in bleeding, 291-305
in blighted ovum diagnosis, 292-293
and chorionic gonadotropin levels, 301, 305
in chorionic villi sampling, 308-309
crown-rump measurement in, 290-291
in ectopic pregnancy, 297-305
in elective abortion, 307-308
gestational sac dimensions in, 289-290
in gestational trophoblastic disease, 295-297
landmarks in, 288-289
in missed abortion, 293
placental patterns in, 327-328
in removal of IUD, 306-307
and uterine curettage after spontaneous abortion, 307-308
in gestational age estimation, 289, 314-325
abdominal circumference in, 320-322, 345
biparietal diameter in, 315-319, 344
crown-rump measurements in, 290-291, 315, 344
diameter of gestational sac in, 289-290, 315
femur length in, 322-323, 345
head circumference in, 319-320, 344-345
multiple measurements in, 323

in hydatidiform mole, 182, 187-189
instrumentation in, 286
in intrauterine growth retardation, 342-347
  body proportionality in, 346
  head size in, 344-345
  length in, 345-346
  in oligohydramnios, 346-347
  total intrauterine volume in, 346
  trunk size in, 345
  weight in, 346
in intrauterine transfusions, 72-73
in labor management of twin pregnancies, 74-75
in lung maturity diagnosis, 391-399. *See also* Fetus, lung maturity diagnosis
in macrosomia of fetus, 347-349
maternal pelvis in, 277, 287
in monitoring of ovulation induction, 993-1001
in multiple gestation, 352-357
  in abortion of one fetus, 293-294
  and amniocentesis, 355-356
  congenital anomalies in, 356
  diagnostic use of, 352-353
  fetal growth studies in, 354-355
  and perinatal outcome, 356-357
in neural tube defect detection, 79
in pelvic masses, 402-414
  bicornuate uteri, 413
  complex masses, 410-411
  differential diagnosis in, 403-404
  fecal impaction, 413
  hematoma of abdominal wall, 413
  inflammatory masses, 413
  multilocular cysts, 409-410
  ovarian tumors, 407-409
  pelvic kidney, 413
  solid masses, 411-413
  unilocular cysts, 409
  uterine myomas, 404-407
  uterine rupture, 413
placental imaging in, 327-340
  in abruption of placenta, 335-336
  in amniotic band syndrome, 339
  in chorangiomas, 336-337
  in first trimester, 327-328
  maturational changes in, 329-334, 347, 393
  in placenta previa, 334-335
  positional changes in, 334
  in retention of fragments, 337-339
  in second and third trimester, 328-329
  in succenturiate lobes, 337
  umbilical cord vessels in, 339
preparation of patient for, 287
review questions on, 426-427
safety and long-term effects of, 269-275
technique of, 276-277
and treatment of fetus in utero, 369, 378-389. *See also* Fetus, treatment in utero
in vaginal bleeding
  first-trimester, 68-70
  third-trimester, 73-74
Umbilical cord, ultrasonography of, 339
Urethra
  anatomy of, 436
  diverticulum of, 490-498
    diagnosis of, 492-493
    etiology of, 490-491
    marsupialization procedures in, 497
    nonsurgical procedures in, 497
    operative technique in, 493-497
    postoperative complications in, 496-497
    recurrent, 496
    symptoms of, 491-492
  pressure profile for, 441
  spasticity of, 519-520
    treatment of, 526-527
  stenosis of, 518-519
    treatment of, 526
  unstable, 484-485
Urethral syndrome, 515-528
  in allergy, 521-522
  in chronic urethritis, 516-517
    treatment of, 524-525
  diagnosis of, 522-524
  etiology and pathogenesis of, 516-522
  in hypoestrogenic urethritis, 517-518
    treatment of, 525-526
  in infection, 520-521
    treatment of, 527
  in neurologic disorders, 522
  psychogenic, 521
    treatment of, 527
  treatment of, 524-527
  in urethral stenosis and spasm, 518-520
    treatment of, 526-527
  and vaginismus, 757
Urethritis
  chronic, 516-517
    treatment of, 524-525
  compared to detrusor instability, 482-484
  hypoestrogenic, 517-518
    treatment of, 525-526
Urethrolysis, in urethral syndrome, 526
Urethroscopy
  in urethral syndrome, 523
  in urinary incontinence, 442, 464
Urethrotomy, internal, in urethral syndrome, 526
Urethrovaginal fistula repair, 505-511
Uric acid levels, in hypertension in pregnancy, 840, 844, 869
Urinary tract infections in pregnancy, 874-888
  antimicrobial therapy in, 878-880
  asymptomatic bacteriuria in, 880-883
  cystitis in, acute, 883-884
  fetal effects of, 877-878
  laboratory studies in, 875-877
  long-term maternal effects of, 886-887

microorganisms in, 875
prophylaxis and suppression in, 887-888
pyelonephritis in, 17-29, 884-886, 898
Urine
diversion of, and pregnancy management, 898
fetal, stimulating prostaglandin formation, 566-567
incontinence of. *See* Incontinence, urinary
Uroflowmetry
in urethral syndrome, 523
in urinary incontinence, 441
Urology, 429-529
diverticulum of urethra, 490-498
incontinence. *See* Incontinence, urinary
infections in pregnancy, 874-888
review questions on, 531
role in gynecology, 431-433
urethral syndrome, 515-528
Uropathies, obstructive, treatment in utero, 380-385
Uteroplacental bed, in pregnancy with chronic hypertension, 859-860
Uretus. *See also* Cervix uteri; Myometrium
atony of, and postpartum hemorrhage, 139-141
bicornuate, in pregnancy, ultrasonography of, 413
contractility of, 573-575, 593-596
curettage of. *See* Curettage, uterine
enlargement in molar pregnancy, 185
innervation of, 580-581
inversion during labor, 134-137, 142
magnesium sulfate affecting, 90, 601-602
myomas in pregnancy, ultrasonography of, 404-407
myometrial function in labor, 572-590
oxytocin affecting, 89, 586-588. *See also* Oxytocin infusions
rupture of
in induced abortion, 413
postpartum, 141
tocolytic agents affecting. *See* Tocolytic agents
ultrasonic visualization of, 277, 287

Vagina
bleeding from
first-trimester, 68-70
in hydatidiform mole, 184-185
third-trimester, 73-74
blood flow in, measurements of, 769-770
in sleep, 777
electropotential difference, transvaginal, 721
engorgement in sexual response
physiologic measures of, 769-770
postmenopausal, 775-776
G spot in, 701-705
infections in lesbians, 724-725
lacerations in labor, 142-143
lubrication during sexual response, 699-700, 770
in menopause, 720
pH values in, 721
urethrovaginal fistula repair, 505-511
vesicovaginal fistula repair, 504
Vaginismus, 736, 754-756
treatment of, 756
and urethral syndrome, 757
Vasoactive intestinal polypeptide levels in plasma, and sexual arousal, 772
Vasoconstrictor tone, in pregnancy-induced hypertension, 822-827
Ventriculoamniotic shunts, in fetal hydrocephalus, 81, 387-388
Vesicoamniotic shunt placement, in fetal obstructive uropathy, 384-385
Vesicovaginal fistula repair, 504
Vomiting, in molar pregnancy, 185
VP16-213, in metastatic gestational trophoblastic neoplasia, 236

Weight
fetal
estimates of, 70-72
in growth retardation, 346
in macrosomia, 349
in low birth weight infants. *See* Preterm birth and low-weight amenorrhea, 947-948
maternal, and pregnancy outcome, 554-555

STATEMENT OF OWNERSHIP, MANAGEMENT AND CIRCULATION
(Act of August 12, 1970: Section 3685, Title 39, United States Code)

1. *Title of publication:* Clinical Obstetrics and Gynecology. *Pub. no.:* 118300
2. *Date of filing:* October 1, 1984
3. *Frequency of issue:* Quarterly
   A. *No. of issues published annually:* 4
   B. *Annual subscription price:* $52 Pers. $68 Inst. U.S.
4. *Location of known office of publication:* 2350 Virginia Avenue, Hagerstown, MD 21740
5. *Location of the headquarters or general business offices of the publishers:* East Washington Square, Philadelphia, PA 19105
6. *NAMES AND COMPLETE ADDRESSES OF PUBLISHER, EDITOR, AND MANAGING EDITOR: Publisher:* Harper & Row, Publishers, Inc., East Washington Square, Philadelphia, PA 19105; *Editor:* Roy M. Pitkin, M.D., Department of Obstetrics and Gynecology, Univ. of Iowa College of Medicine, Iowa City, IA 52242; *Managing Editor:* Deborah G. Huey, East Washington Square, Philadelphia, PA 19105.
7. *OWNER:* Harper & Row, Publishers, Inc., 10 East 53rd Street, New York, NY 10022
8. *HARPER & ROW, PUBLISHERS, INC., STOCKHOLDERS OWNING OR HOLDING 1% OR MORE OF TOTAL AMOUNT OF STOCK:* Cede & Co-M, P.O. Box 20, Bowling Green Sta., New York, NY 10004; Cede & Co., Box 20, Bowling Green Sta., New York, NY 10004; Harper & Row Publishers, Inc., 10 East 53rd St., New York, NY 10022; Fidelity Philadelphia Trust Co., Trustee Estate of Walter Lippincott, Philadelphia, PA 19101; Margaret R. Mertz, 2150 Ibis Isle Road, Palm Beach, FL 33480; Cass Canfield, Jr., & Bernard F. Joyce, Tr UA Nov 19 53, c/o Emmet Marvin & Martin, 48 Wall St., New York, NY 10005; Kray & Co., c/o Midwest Stock Exchange Clearing Corporation, 120 S. La Salle St., Chicago, IL 60603; Emma Lucile Cullen, 172-70 Highland Ave. Apt 8D, Jamaica Estates, Jamaica, NY 11432; Philadep & Co., 1900 Market Street, 2nd Floor, Philadelphia, PA 19103; Pacific & Co., P.O. Box 7625, San Francisco, CA 94120; Murray R. Spiegel, 39 Willys Street, East Hartford, CT 06108. *HARPER & ROW, PUBLISHERS, INC., DEBENTURE HOLDERS OWNING OR HOLDING 1% OR MORE OF TOTAL AMOUNT OF DEBENTURES:* Marjorie Guttag, c/o Kaufman Alsberg & Co., 61 Broadway, New York, NY 10006; Marjorie S. Isaac, P.O. Box 456, Tuckahoe, NY 10707; Mrs. Jeanne Kanders, 2 Shepard Place, Convent Station, NJ 07961; Ralph Kanders, 20 Trinity Place, Montclair, NJ 07042; Winthrop Knowlton, 10 East 53rd Street, New York, NY 10022; CEDE & Co., c/o The Depository Trust Company, P.O. Box 20, Bowling Green Station, New York, NY 10274.
9. Not applicable
10. *Extent and nature of circulation*

	Av. each issue, preceding 12 mo.	Issue nearest to filing date
Total no. copies printed	12,294	12,200
Paid circulation		
1) through dealers & carriers, street vendors and counter sales	—	—
2) mail subscriptions	11,093	11,052
Total paid circulation	11,093	11,052
Free distribution	72	90
Total distribution	11,165	11,142
Office use, leftover, unaccounted, spoiled after printing	1,129	1,058
Total	12,294	12,200

11. *I certify that the statements made by me above are correct and complete.* Joseph W. Lippincott, III, Associate Publisher

AUTHOR INDEX

Archer, David F., 917, 919
Bakketeig, Leiv S., 539
Berkowitz, Ross S., 221
Bernstein, Marilyn R., 221
Bezjian, Alex A., 402
Blanco, Jorge D., 60
Boehm, Frank H., 78
Brumfield, Cynthia G., 50, 68
Bryant, Donna M., 672
Buckley, Jonathan D., 153
Casey, M. Linette, 562
Cavanagh, D., 3
Cefalo, Robert C., 139
Chang, Frank E., 941
Chesley, Leon C., 801
Davis, Lowell E., 445
Davis, Richard O., 68
Davison, J. M., 891
De Vore, Greggory R., 359
DeCherney, A. H., 993
DeVoe, Stephen J., 836
Deter, Russell L., 342
Driscoll, Shirley G., 160
Duff, Patrick, 17
Enkin, Murray W., 606
Fanaroff, Avory A., 636, 647
Fantl, J. Andrew, 474
Garfield, R. E., 572
Golde, Steven H., 391
Goldenberg, Robert L., 95
Goldstein, Donald Peter, 221
Gottesfeld, Kenneth R., 327
Hack, Maureen, 647
Hadlock, Frank P., 342
Hammond, Charles B., 228
Hammond, D. Corydon, 732
Harman, C., 378
Harris, Bruce A., Jr., 106, 134
Harris, Robert E., 874
Harrist, Ronald B., 342
Herbert, William N. P., 139
Hillier, Stephen G., 927
Hobbins, John C., 286
Hoffman, Howard J., 539
Hohler, Charles W., 314, 416
Hoon, Peter W., 767
Huddleston, John F., 1, 50, 84
Jeanty, Philippe, 286
Johnson, Susan R., 724
Keye, William R., Jr., 695, 760
Kim, Moon H., 941
Knox, G. Eric, 11
Knuppel, Robert A., 3
Kohorn, Ernest I., 181
Kremkau, Frederick W., 269
Kristal, Alan R., 553
LaFerla, John J., 738
Lange, I. R., 378
Laufer, N., 993
Lee, Raymond A., 490
Lindheimer, M. D., 891
Liu, James H., 975
MacDonald, Paul C., 562
Makowski, Edgar L., 902
Manning, F. A., 378
March, Charles M., 966
Marchant, Douglas J., 434
Martin, James N., Jr., 39
Martin, Richard J., 636
Mattingly, Richard F., 429, 445
McCarton, Cecelia M., 664
Medearis, Arnold L., 276
Meier, Paul R., 902
Merkatz, Irwin R., 537
Milner, Ruth A., 606
Mohide, Patrick T., 606
Morrison, I., 378
Morrison, John C., 39
Morrow, C. Paul, 151, 211
Mueller-Heubach, Eberhard, 1003

Nelson, Kathleen G., 95
O'Brien, Timothy J., 240
O'Shaughnessy, Richard, 836
Ostergard, Donald R., 515
Palermo, Jefri L., 724
Papiernik, Emile, 614
Patterson, Robert M., 32
Perkins, Richard P., 706
Philips, Joseph B., III, 125
Platt, Lawrence D., 267, 391
Quigley, Martin M., 983
Ramey, Craig T., 672
Rao, Papineni S., 3
Reamy, Kenneth, 782
Roberts, James M., 592
Romero, Roberto, 286
Rush, David, 553
Sabbagha, Rudy E., 352
Schaeffer, Anthony J., 459
Schlaerth, John B., 192
Schnitker, Korliss A., 11
Scotti, Richard J., 515
Scully, Robert E., 248
Semmens, Eva Curtis, 717
Semmens, James P., 717
Shaw, D. Barry, 112
Shields, James R., 276
Socol, Michael L., 352
Soper, John T., 228
Sparling, Joseph J., 672
Steege, John F., 750
Surti, Urvashi, 172
Symmonds, Richard E., 499
Szulman, A. E., 172
Tamura, Ralph K., 352
Twiggs, Leo B., 199
Vaughan, Herbert G., Jr., 664
Warenski, James C., 431
Wasik, Barbara H., 672
Weisberg, Martin, 697
Welch, Kathryn A., 125
Wheeler, A. Scott, 112
Worley, Richard J., 821
Wu, Chung H., 953
Yen, S. S. C., 975
Young, Robert H., 248
Zeleznik, Anthony J., 927
Zuspan, Frederick P., 797, 854